Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[leifsmith]

Patrick Cox has produced his first newsletter for Mauldin Economics. The title of the 25 page letter is "Reprogramming Immune Systems with DNA Vaccines for Health and Wealth." It does not mention STSI or the non-vaccine nanoviricide that he's covered previously. I have not read this newsletter yet, only scanned it. It's clear that it will be fascinating reading.

A small excerpt compares the declining cost of sequencing a genome with Moore's law (computers):

One easily measured consequence of this dynamic is the plummeting cost of sequencing a genome. Progress in genome sequencing is advancing twice as fast as Moore’s Law. Clearly, this is not simply due to the cost and power of the chips used in sequencing machines. It is also the product of associated advances in scientific knowledge.

A chart is provided illustrating the comparative rates of decline.

The letter covers only one company, Inovio Pharmaceuticals, and concludes with a careful recommendation of how to buy the stock. There is no wild pumping or ecstatic recommendation. I regard his proposed strategy as measured and wise. He warns against buying at moments of irrational expectation of quick wealth, when the stock is spiking.

Anyone who thinks that because Cox has limited his first letter to this single company that his interest in STSI, or the nanoviricide company, has declined is probably wrong. I would expect he will wait until the next major event, probably publication of a study on thyroiditis before he covers STSI again. I can wait.

Cox's work continually attracts ignorant or malicious detractors, but I believe he is one of the most competent and informative researchers delivering information on biotech to average investors who are not scientific experts. I have learned an enormous amount from him.